8-K current report · filed Aug 6, 2026

Intellia Therapeutics, Inc. (NTLA) 8-K Current Report: August 6, 2026

Item EX-99.1Item 2.02NTLA overview

Short answer

Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Intellia’s August 6, 2026 announcement covers financial results for the quarter ended June 30, 2026.

Intellia Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Intellia’s August 6, 2026 announcement covers financial results for the quarter ended June 30, 2026
  • Business updates accompanied the quarterly results announcement
  • Full results and operating details are in Exhibit 99.1, the furnished press release

Item EX-99.1 · Exhibit EX-99.1

  • Positive Phase 3 HAELO data: lonvo-z reduced attacks 87% versus placebo, with 62% attack-free and therapy-free versus 11%
  • FDA BLA acceptance anticipated in second half of 2026, with potential U.S. launch in first half of 2027
  • Nex-z Phase 3 enrollment resumed; MAGNITUDE-2 ATTRv-PN enrollment targeted for completion in second half of 2026
  • Genomic analysis identified an HLA allele associated with highest liver transaminase elevations, creating a safety-monitoring and regulatory focus
  • Cash $628.4M after $195M net offering proceeds, expected to fund operations at least into 2028; Q2 net loss $106.6M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Intellia Therapeutics, Inc. 8-K filings

Get the next NTLA 8-K as it lands

Follow NTLA for push alerts, or ask the research agent what this filing means.